- Troy Healthcare buys Stopain, announces line extension
- Performance Health introduces Perform Pain Relieving Spray
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- SymphonyIRI: Younger boomers shift to dollar channel versus drug in vitamins, internal analgesics
- Aroma Naturals launches skin care line
HAZLETON, Pa. — Troy Healthcare in January acquired the distribution of its Stopain brand, an external analgesic Troy has been manufacturing since 2002 that is already an up-and-coming pain-relief spray. The brand cracked the top 10 list of external analgesic rubs for the 12 weeks ended Dec. 26, 2010, moving into the No. 10 spot with $1.3 million in sales across food, drug and mass (excluding Walmart), according to SymphonyIRI Group data. SKU growth of 16.1% in that period also is outpacing category growth of 11.3%.
And already Troy has a line extension in the works: a new Stopain pain-relieving gel that contains 38% more of the active ingredient menthol than any other product in the cooling gel category, the company stated.
Suggested retail price for the pain-relieving gel will be $5.99 for a 2.5-oz. tube. This is very much a value-priced item that is primed to succeed in today’s economy, Troy Healthcare spokesman Bob Miller said.